NuCana (NASDAQ:NCNA) Releases Quarterly Earnings Results, Beats Estimates By $1.66 EPS

NuCana (NASDAQ:NCNA) posted its quarterly earnings results on Thursday. The company reported ($0.99) EPS for the quarter, topping analysts’ consensus estimates of ($2.65) by $1.66, Zacks reports.

NuCana Trading Up 3.5%

NCNA stock traded up $0.05 during trading hours on Thursday, hitting $1.48. 15,645 shares of the stock traded hands, compared to its average volume of 35,395. The stock has a 50-day simple moving average of $1.52 and a 200 day simple moving average of $1.87. The company has a market cap of $6.16 million, a P/E ratio of -0.50 and a beta of 2.25. NuCana has a one year low of $1.21 and a one year high of $7.22.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of NuCana in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

About NuCana

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.